Teva Pharmaceutical Industries Ltd (ADR) (N:TEVA)

May 08, 2024 07:00 am ET
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended March 31, 2024.
May 08, 2024 06:30 am ET
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL), today announced results from the efficacy portion of the Phase 3 Subcutaneous OLAnzapine extended-Release Injection Study (SOLARIS) trial evaluating TEV-‘749 in adult patients with schizophrenia compared to placebo. Results demonstrated that TEV-‘749 met its primary endpoint as measured by a change in the PANSS total score from baseline after 8 weeks compared to placebo. TEV-‘749 utilizes SteadyTeq™, a copolymer technology proprietary to Medincell that pr
May 02, 2024 06:30 pm ET
Teva to Present at the 2024 Bank of America Healthcare Conference
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 2024 Bank of America Healthcare Conference on Tuesday, May 14, 2024. The presentation will begin at 8:40 A.M. Pacific Time (11:40 A.M. Eastern Time).
May 02, 2024 08:30 am ET
Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its
Apr 30, 2024 04:00 am ET
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE:...
Apr 30, 2024 04:00 am ET
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), disclosed today that under the recently announced U.S. strategic partnership agreement, Alvotech will manufacture its high-concentration interchangeable biosimilar to Humira® (adalimumab) for Quallent Pharmaceuticals with, in alignment with its U.S. commercialization agreement with Teva. The interchangeable biosimilar will be distributed under Qua
Apr 16, 2024 05:43 pm ET
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older. Under the strategic partnership between Teva and Alvotech, Teva is responsible for the exclusive commercialization of SELARSDI in the United States.
Apr 16, 2024 05:30 pm ET
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) injection for...
Apr 16, 2024 08:00 am ET
Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tabl
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced final results from the HD cohort of the Phase 4 START study, demonstrating positive real-world effectiveness, safety, adherence and satisfaction with the 4-week Titration Kit for AUSTEDO. As a fatal, neurodegenerative disease, HD can cause cognitive deterioration, behavioral and/or psychological problems and uncontrollable body movements known as chorea – a symptom that can have a significant impact on daily activities like eating or talking.3-5 These data are
Apr 11, 2024 08:30 am ET
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced results from a Phase 3 study evaluating the efficacy and safety of AJOVY for the prevention of migraine in adult Chinese patients.
Apr 09, 2024 04:30 pm ET
Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2024 financial results on Wednesday, May 8, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
Apr 06, 2024 01:00 pm ET
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of eight studies from its LAI schizophrenia research program, including data evaluating UZEDY, an extended-release injectable suspension of risperidone for subcutaneous use every one or two months for the treatment of schizophrenia in adults. The data were presented at the 2024 Congress of the Schizophrenia International Research Society (SIRS) taking place from April 3-7, 2024 in Florence, Italy.
Apr 04, 2024 08:30 am ET
Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, today announced they have entered a strategic licensing agreement for a biosimilar candidate currently in development for the treatment of multiple oncology indications. Biosimilars show promising potential in providing more cost-effective alternatives to existing oncology therapies, thereby addressing a critical need in global oncology care.
Apr 01, 2024 08:30 am ET
Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Launch Therapeutics, Inc., today announced a clinical collaboration agreement to further accelerate the clinical research program of Teva’s ICS-SABA (TEV-‘248). Teva and Abingworth, a leading international life sciences investment group, part of global investment firm Carlyle (NASDAQ: CG), today also announced a strategic development funding agreement in which Abingworth provides Teva up to $150 million to offset Teva’s ICS/SABA (TEV-‘248) program costs.
Feb 26, 2024 07:00 am ET
Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China
Teva Pharmaceutical Investments Singapore Pte Ltd (TPIS), a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Jiangsu Nhwa Pharmaceutical Co., Ltd (“Nhwa”) today announced it formed a partnership for the marketing and distribution of Teva’s AUSTEDO (deutetrabenazine) for the treatment of neurodegenerative and movement disorders - chorea associated with Huntington’s disease (HD) and tardive dyskinesia (TD) in adults. The partnership intends to increase patients’ access to Teva’s AUSTEDO, leveraging Nhwa’s leadership in China’s neuro-psychiatric health sector.
Feb 23, 2024 08:15 pm ET
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SIMLANDI (adalimumab-ryvk) injection, as...
Feb 23, 2024 08:15 pm ET
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SIMLANDI (adalimumab-ryvk) injection, as an interchangeable biosimilar to Humira, for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis. In 2023, Humira was one of the highest grossing pharmaceu
Feb 20, 2024 08:30 am ET
Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced positive safety, tolerability, and pharmacokinetic data for its anti-TL1A (TEV-’574) asset, a potentially best-in-class human IgG1 monoclonal antibody that targets the tumor necrosis factor (TNF)-like ligand 1A (TL1A) and is designed to offer both anti-inflammatory and anti-fibrotic effects.1-3
Jan 31, 2024 07:00 am ET
Teva Reports Growth in Fourth Quarter and Full Year 2023
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2023.
Jan 31, 2024 06:00 am ET
Teva Announces Intention to Divest API Business as Part of Pivot to Growth Strategy
Teva announced today its intention to divest its active-pharmaceutical ingredient (API) business, or "TAPI". TAPI is a global leader in the small-molecule API industry, with approximately 4,300 employees worldwide.
Jan 02, 2024 04:30 pm ET
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Guidance at 8 a.m. ET on January 31, 2024
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2023 financial results, as well as on its financial guidance for 2024, on Wednesday, January 31, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
Dec 28, 2023 04:30 pm ET
Teva to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024. The presentation will begin at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time).
Dec 14, 2023 08:30 am ET
Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma
Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) and Biolojic Design Ltd. ("Biolojic"), a biotechnology company that uses computational biology and artificial intelligence to transform antibodies into intelligent medicinal solutions, today announced an exclusive license agreement to develop a potential novel antibody-based therapy for the treatment of Atopic Dermatitis and Asthma.
Dec 06, 2023 02:00 am ET
New Post Hoc Phase 3 Data Analysis Shows AJOVY® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid Obesity
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announces that a post hoc analysis4 of two phase 3 clinical studies presented today at the European Headache Congress has shown the effectiveness of the migraine prevention treatment AJOVY® (fremanezumab) in reducing migraine attacks in patients with migraine and co-morbid obesity.
Nov 30, 2023 08:30 am ET
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today closing of its collaboration deal to co-develop and co-commercialize asset TEV ‘574 with Sanofi (EURO
Nov 20, 2023 04:30 pm ET
Teva to Present at the 6th Annual Evercore ISI HealthCONx Conference
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023. The presentation will begin at 8:20 A.M. Eastern Time.
Nov 17, 2023 08:30 am ET
Teva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S.
Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the approval of a generic version of Forteo®1, in the United States. Market availability of the product in the U.S. is expected in the coming weeks.
Nov 13, 2023 08:10 am ET
Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program
Royalty Pharma plc (Nasdaq: RPRX) and Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today a collaboration to further accelerate the clinical research program for Teva’s...
Nov 13, 2023 08:00 am ET
Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Royalty Pharma plc (Nasdaq: RPRX), announced today a collaboration to further accelerate the clinical research program for Teva’s olanzapine LAI (TEV-‘749) by entering into a funding agreement of up to $125 million to offset program costs. Olanzapine LAI (TEV-‘749) is a once-monthly subcutaneous long-acting injection of the atypical antipsychotic olanzapine that is currently in Phase 3 for the treatment of schizophrenia and has the potential to be the first long-acting olanzap
Nov 08, 2023 07:00 am ET
Teva Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended September 30, 2023.
Nov 07, 2023 04:30 pm ET
Teva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients Business
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Dr. R. Ananthanarayanan (Ananth) as CEO of its Teva Active Pharmaceutical Ingredients business (Teva api). Dr. Ananth will lead the API business starting November 27, 2023, and will be based out of Teva's U.S. headquarters in Parsippany, NJ.
Nov 02, 2023 08:00 am ET
Teva to Present New Data Supporting Safety, Efficacy and Real-World Effectiveness of AUSTEDO® (deutetrabenazine) Tablets at the 2023 HSG Annual Meeting
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new HD data will be presented at the Huntington Study Group® (HSG) Annual Meeting on November 2-4 in Phoenix, AZ.
Nov 01, 2023 07:31 pm ET
UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolongs Time to Schizophrenia Relapse in RISE Study Results Published in The Lancet Psychiatry
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the publication of efficacy and safety findings from the phase 3 Risperidone Subcutaneous Extended-Release (RISE) study in The Lancet Psychiatry. The data supported the FDA approval for UZEDY, which was approved in April 2023 for the treatment of schizophrenia in adults as a subcutaneous injection every one or two months using a pre-filled syringe.
Oct 25, 2023 09:00 am ET
Teva to Provide Second Round of Funding to Clinics in California, Florida and New Jersey as Part of $2 Million Commitment Through Community Routes: Access to Mental Health Care Program
Direct Relief, the National Association of Free and Charitable Clinics (NAFC), and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the continued funding of 11 local free and charitable clinics in the U.S. as part of a $2 million, two-year commitment, through their collaborative Community Routes: Access to Mental Health Care program that aims to advance access to healthcare for uninsured patients seeking treatment for anxiety and depression.
Oct 17, 2023 01:30 am ET
Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announce that data from the UNITE study presented today at the World Congress of Neurology in Montreal, Canada, show that AJOVY® (fremanezumab) reduced migraine attacks and depression symptoms in migraine patients with major depressive disorder. AJOVY® is currently approved for the preventive treatment of migraine in adults.
Oct 06, 2023 04:30 pm ET
Teva to Host Conference Call to Discuss Third Quarter 2023 Financial Results at 8 a.m. ET on November 8, 2023
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2023 financial results on Wednesday, November 8, 2023, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast, at 8:00 a.m. ET.
Oct 04, 2023 01:07 am ET
Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment
Sanofi (EURONEXT: SAN and NASDAQ: SNY) and Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announce today a collaboration to co-develop and co-commercialize asset TEV ‘574, currently in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn's Disease, two types of inflammatory bowel disease.
Sep 28, 2023 04:05 pm ET
Teva Announces Changes to Executive Management Team
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced changes to its leadership team. Sven Dethlefs, Executive Vice President, North America Commercial, will leave Teva on November 17, 2023, and Christine (Chris) Fox, who most recently served as Global President, Gene Therapies at Novartis will be the new head of Teva’s U.S. Commercial Business. “On behalf of the Teva Board of Directors and our executive management team, I want to thank Sven for his many contributions to Teva during his 15 years with the company,” said Richard Francis, Teva’s President, and Chief Executive
Sep 06, 2023 04:30 pm ET
Teva to Present at the 21st Annual Morgan Stanley Global Healthcare Conference
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Morgan Stanley Global Healthcare Conference on Monday, September 11, 2023. The presentation will begin at 8:40 A.M. Eastern Time.
Sep 06, 2023 08:00 am ET
Teva to Present Data for AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO® (deutetrabenazine) Tablets and UZEDY™ (risperidone) Extended-Release Injectable Suspension at Psych Congress
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced 16 data presentations across its neuroscience portfolio happening at Psych Congress on September 6-10 in Nashville, TN. Abstracts include data for AUSTEDO, once-daily AUSTEDO XR, UZEDY, TV-44749 and AJOVY. Once-daily AUSTEDO XR, a new formulation of twice-daily AUSTEDO was approved by the U.S. Food and Drug administration (FDA) in February 2023 for adults with TD and chorea associated with Huntington’s disease (HD), and UZEDY, a long-acting formulation of risperidone for
Aug 21, 2023 04:00 pm ET
Teva Settles Price Fixing Charges With U.S. DOJ
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), has reached a deferred prosecution agreement (DPA) with the U.S. Department of Justice (DOJ) to settle the criminal price-fixing charges brought against Teva in 2020.
Aug 02, 2023 07:00 am ET
Teva Reports Second Quarter 2023 Financial Results
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended June 30, 2023.
Jul 27, 2023 08:00 am ET
Teva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business Development
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Dr. Angus Grant, Ph.D., as EVP, Business Development. Dr. Grant will begin his employment on August 1, 2023, and will be based out of Teva's US headquarters in Parsippany, NJ.
Jul 24, 2023 04:00 am ET
Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership
Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), a global leader in generic and innovative medicines and Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and...
Jul 24, 2023 04:00 am ET
Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership
Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), a global leader in generic and innovative medicines and Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that they have agreed to expand their existing strategic partnership agreement. Teva will also acquire subordinated convertible bonds to be issued by Alvotech.
Jul 05, 2023 04:30 pm ET
Teva to Host Conference Call to Discuss Second Quarter 2023 Financial Results at 8 a.m. ET on August 2, 2023
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2023 financial results on Wednesday, August 2, 2023 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast, at 8:00 a.m. ET.
Jun 30, 2023 12:30 pm ET
Teva’s 3rd interim analysis of PEARL real-world study on AJOVY® (fremanezumab) reveals sustained long-term effectiveness in reducing frequency, duration and severity of attacks in patients with chroni
Teva Pharmaceutical Industries Ltd. today announces further positive data from the pan-European PEARL study investigating the impact of AJOVY® (fremanezumab) on the prevention of migraine in a real-world setting,1 due to be completed in 2024.
Jun 15, 2023 08:00 am ET
Teva to Present Data at the 2023 American Headache Society Annual Scientific Meeting Demonstrating AJOVY® (fremanezumab-vfrm) Injection Significantly Reduced Migraine and Depression Symptoms in Patien
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that six abstracts revealing benefits of AJOVY (fremanezumab-vfrm) injection in patients with migraine will be presented at the 2023 American Headache Society (AHS) Annual Scientific Meeting, held June 15-18 in Austin, Texas.
Jun 12, 2023 04:00 pm ET
Teva Reaches Agreement With Kentucky to Settle the State’s Price Fixing Claims
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), has reached agreement with the Attorney General of Kentucky to settle the state’s price-fixing claims against Teva. Under the terms of the settlement, Teva will pay the state $1.407 million, and the state will dismiss all of its claims against Teva and its affiliates once payment has been made.
Jun 12, 2023 07:00 am ET
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced they have reached a settlement and license agreement with Johnson & Johnson (NYSE:JNJ) concerning AVT04, Alvotech’s proposed biosimilar to Stelara® (ustekinumab) in the United States. The settlement grants a license entry date for AVT04 in the United States no later than February 21, 2025.
Jun 12, 2023 03:00 am ET
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and...
Jun 08, 2023 08:30 am ET
Teva Concludes Nationwide Opioids Settlement Agreement
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the Company has fully resolved its nationwide settlement agreement related to opioid claims brought by U.S. states, their subdivisions, and special districts, and has reached a separate settlement with the final state of Nevada. Teva will pay Nevada $193 million over 20 years (including all fees and costs), and this settlement resolves the case prior to trial, which had been scheduled to begin in August 2023.
Jun 06, 2023 08:00 am ET
Phil and Teva Pharmaceuticals Launch New Program to Improve Access to the Digihaler® Family of Inhalers to Support Asthma Management
Phil Inc., a patient access platform company that revolutionizes life science product commercialization, today announced an agreement with Teva Pharmaceuticals that will make Digihaler® products available for prescription using the PhilRx Patient Access Platform. Teva’s Digihaler system is the first and only smart inhaler system that can provide objective inhaler da
Jun 02, 2023 04:30 pm ET
Teva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration Kit at Psych Congress Elevate 2023
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced 12 presentations across its neuroscience portfolio featured at the Psych Congress Elevate 2023 Annual Meeting taking place on June 1-4, 2023. Two presentations feature real-world data for AUSTEDO (deutetrabenazine) tablets for adults living with TD. Data presented will include interim findings from the START trial, a Phase 4 study investigating real-world utilization of AUSTEDO with a 4-week patient titration kit along with treatment success as measured at the end of trea
May 20, 2023 11:00 am ET
Teva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatr
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that four studies across its neuroscience portfolio will be presented during the American Psychiatric Association’s (APA) 2023 Annual Meeting taking place on May 20-24, 2023. Abstracts include data for UZEDY (risperidone) extended-release injectable suspension for subcutaneous use, which was recently approved by the FDA for the treatment of schizophrenia in adults. Additional abstracts being presented include data on characteristics that impact TD diagnosis and machine-le
May 18, 2023 08:30 am ET
Teva Launches New “Pivot to Growth” Strategy
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a new strategic framework with four main pillars to position the Company for a new era of growth. This strategy aims to bolster the Company’s strong commercial portfolio with AUSTEDO®, AJOVY®, UZEDYTM and biosimilars, amplify its innovative pipeline, sustain its generics powerhouse and focus the business. These four pillars are expected to deliver enhanced value and create a greater impact for patients.
May 15, 2023 08:00 am ET
AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, New Once-Daily Formulation of AUSTEDO®, Now Available in the U.S.
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that once-daily AUSTEDO XR (deutetrabenazine) extended-release tablets are now available for adults in the United States in 6 mg, 12 mg and 24 mg tablet strengths. AUSTEDO XR was recently approved by the U.S. Food and Drug Administration (FDA) for adults living with tardive dyskinesia (TD) and chorea associated with Huntington’s disease (HD). AUSTEDO is the only vesicular monoamine transporter 2 (VMAT2) inhibitor with 3-year data that is indicated in adults for bot
May 10, 2023 07:00 am ET
Teva Reports First Quarter 2023 Financial Results and Reaffirms 2023 Non-GAAP Outlook
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended March 31, 2023.
May 09, 2023 07:00 am ET
Teva Shares Progress Toward Access to Medicines and Environmental Commitments, Meeting and Exceeding Several ESG Targets Ahead of Schedule
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2022 Environmental, Social and Governance (ESG) Progress Report, which highlights the Company's achievements, such as completing more than 40% of its 23 long-term targets, including si
May 03, 2023 08:30 am ET
U.S. Mental Health Access Program Expands Medicine Donation to Seven New States
Direct Relief, the National Association of Free and Charitable Clinics (NAFC), and Teva Pharmaceuticals, U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced an expansion of medicine donations through their collaborative mental health access program into seven new states to advance access to healthcare for uninsured patients seeking treatment for anxiety and depression.
Apr 28, 2023 07:22 pm ET
Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and MedinCell (Euronext: MEDCL) announced today that the U.S. Food and Drug Administration (FDA) has approved UZEDY (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults. UZEDY is the first subcutaneous, long-acting formulation of risperidone that utilizes SteadyTeq™, a copolymer technology proprietary to MedinCell that controls the steady release of risperidone. Therapeutic blood concentrations are reached within 6-24 hours of a single dose.
Apr 27, 2023 08:35 am ET
Teva to Launch New Growth Strategy at Investor Day
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will host an Investor Day on Thursday, May 18, 2023 to launch its new growth strategy and portfolio priorities. The event will take place at the New York Stock Exchange in New York City. Presentations will begin at 12:00 p.m. Eastern Time and are expected to conclude at 2:00 p.m. Eastern Time.
Apr 14, 2023 04:15 pm ET
Teva to Host Conference Call to Discuss First Quarter 2023 Financial Results at 8 a.m. ET on May 10, 2023
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2023 financial results on Wednesday, May 10, 2023 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
Apr 13, 2023 08:53 pm ET
Complete Response Letter Received for AVT02 Biologics License Application
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) to its partner Alvotech (NASDAQ: ALVO) for the Biologics License Application (BLA) for AVT02, a high-concentration biosimilar candidate for Humira® (adalimumab). The CRL stated that the application could not be approved at this time based on deficiencies associated with Alvotech’s manufacturing facility that must be satisfactorily resolved. Additional review of the details following the recent FDA’s re-inspection and CRL are
Apr 11, 2023 08:00 am ET
Teva to Present New Data on Once-Daily AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets at the 2023 American Academy of Neurology Annual Meeting
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced six poster abstracts across its neurology portfolio will be presented at the American Academy of Neurology (AAN) Annual Meeting on April 22-27, 2023. Abstracts include data for AUSTEDO (deutetrabenazine) tablets, as well as once-daily AUSTEDO XR (deutetrabenazine) extended-release tablets. AUSTEDO XR was recently approved by the FDA, as a once-daily formulation of AUSTEDO for adults living with tardive dyskinesia (TD) and chorea associated with Huntington’s disease (HD),
Mar 27, 2023 08:00 am ET
Teva’s Digital Health Collaboration with Rimidi Expands to Include Respiratory Monitoring Program Integration with a Large U.S. Health System
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that a respiratory patient monitoring program using data from Teva’s Digihaler System has been implemented within California’s Desert Oasis Healthcare (DOHC) system. The program was designed in collaboration with Rimidi, a leading clinical management platform designed to optimize clinical workflows, enhance patient experiences and achieve quality objectives. Teva’s Digihaler is the first and only smart inhaler system that can provide objective data to help patients and their doc
Mar 13, 2023 09:33 am ET
Teva Announces Early Tender Results of its Debt Tender Offer, Increases to Tender Caps and Election of Early Settlement
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the early tender results in connection with its previously announced tender offers (the “Offers”) and that it is increasing the tender caps as specified below for the following series of notes issued by finance subsidiaries of Teva and guaranteed by Teva:
Mar 09, 2023 08:00 am ET
Teva and Natco Announce Launch of additional strengths for the Generic Version of Revlimid® (lenalidomide capsules), in the U.S.
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816), announced today the launch of additional strengths for the generic version of Revlimid®1 (lenalidomide capsules), in 2.5 mg, and 20 mg strengths, in the United States.
Mar 07, 2023 04:00 pm ET
Teva to Present at the Barclays Global Healthcare Conference
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Eli Kalif, EVP and Chief Financial Officer will present at the Barclays Global Healthcare Conference on Tuesday, March 14, 2023. The presentation will begin at 10:15 A.M. Eastern Time.
Mar 01, 2023 04:11 pm ET
Teva Announces Successful Upsize and Pricing of $2,490,000,000 (equivalent) Sustainability-Linked Senior Notes and the Increase of the Maximum Tender Amount of its Debt Tender Offer
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it successfully upsized its offering and priced approximately $2,490,000,000 (equivalent) of its sustainability-linked senior notes (the “Notes”). The principal amount of the offering was increased from the previously announced offering size of $2,060,000,000 (equivalent) and the maximum tender amount of Teva’s previously announced debt tender offer was increased from $2,250,000,000 to $2,500,000,000. Teva expects to use the net proceeds from the offerings (i) to fund the announced tender offe
Feb 27, 2023 03:30 am ET
Teva Announces $2,250,000,000 Debt Tender Offers for Notes Due 2023-2026
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it has commenced tender offers (the “Offers”) to purchase for cash for a combined aggregate purchase price (exclusive of accrued and unpaid interest) of up to $2,250,000,000 (the “Total Maximum Amount”) of the following series of notes issued by finance subsidiaries of Teva and guaranteed by Teva:
Feb 27, 2023 03:30 am ET
Teva Announces Launch of $2,060,000,000 (Equivalent) Offering of Sustainability-Linked Senior Notes
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today its intention to issue $2,060,000,000 (equivalent) of sustainability-linked senior notes. The notes offering reflects Teva’s continued strong commitment to sustainable finance to help address some of the greatest challenges of our time. The sustainability-linked senior notes are to be issued under Teva’s sustainability-linked financing framework established in October 2021, as updated in July 2022, which sets forth strategies and targets in accordance with the Sustainability-Linked Bonds Principles (the “
Feb 24, 2023 08:00 am ET
Teva to Present New Data from CONNECT2 Study on its Digihaler® System at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2023 Annual Meeting
Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that new data on its Digihaler System will be presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2023 Annual Meeting, being held February 24-27 in San Antonio, Texas. The data includes findings from the CONNECT2 clinical trial program as well as information on patients and healthcare professionals' real-world use of the smart inhaler system. The Digihaler System is the first and only smart inhaler system with built-in sensors that provid
Feb 23, 2023 08:00 am ET
Teva Announces Publication of New Clinician Scale in Journal of Clinical Psychiatry to Assess the Impact of Tardive Dyskinesia on Patients’ Lives
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the print publication of the IMPACT-TD Scale, an easy-to-use, standardized and clinician-rated assessment. The scale, developed by a consensus panel, will assist healthcare providers in determining the impact of tardive dyskinesia (TD) on different aspects of a patient’s daily functioning.
Feb 17, 2023 04:56 pm ET
Teva Announces FDA Approval of AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, a New Once-Daily Formulation of AUSTEDO® (deutetrabenazine) Tablets
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved AUSTEDO XR (deutetrabenazine) extended-release tablets, a new once-daily formulation indicated in adults for tardive dyskinesia (TD) and chorea associated with Huntington’s disease (HD). AUSTEDO XR is an additional formulation of the currently marketed twice-daily AUSTEDO.
Feb 09, 2023 08:00 am ET
Teva Reaches Agreement With Florida to Settle the State’s Price Fixing Claims
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), has reached agreement with the Attorney General of Florida to settle the state’s price-fixing claims against Teva. Under the terms of the settlement, Teva will pay the state $6.73 million, and the state will dismiss all of its claims against Teva and its affiliates once payment has been made.
Feb 08, 2023 07:00 am ET
Teva Reports Fourth Quarter and Full Year 2022 Financial Results
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2022.
Jan 19, 2023 07:00 am ET
Teva’s Ambitious Climate Targets Externally Validated by the Science Based Targets initiative (SBTi)
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its targets to reduce greenhouse gas (GHG) emissions have been approved by the Science Based Targets initiative (SBTi), providing external validation of the Company’s ambitious commitments to minimize its environmental footprint.
Jan 12, 2023 04:30 pm ET
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results and 2023 Financial Guidance at 8 a.m. ET on February 8, 2023
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2022 financial results, as well as on its financial guidance for 2023, on Wednesday, February 8, 2023 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
Jan 09, 2023 08:00 am ET
Teva Announces Nationwide Opioids Settlement to Move Forward After Receiving Broad Support from States
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today confirmed a sufficient level of participation to move forward with its nationwide settlement agreement to resolve opioid-related claims and litigation by states, cities, counties, and other subdivisions in the United States. Teva has either already settled with or confirmed participation from 48 of the 50 states and will continue to pursue participation by those states that have yet to join. The sign-on process for the states’ subdivisions will now begin. Given the very positive res
Jan 06, 2023 07:00 am ET
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT04, Alvotech’s proposed biosimilar to Stelara® (ustekinumab), which is prescribed to treat a variety of inflammatory conditions. The companies anticipate that the FDA’s review will be completed in second half of 202
Jan 06, 2023 04:00 am ET
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE:...
Jan 03, 2023 04:30 pm ET
Teva to Present at the 41st Annual J.P. Morgan Healthcare Conference
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that members of management will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023. The presentation will begin at 10:30 A.M. Pacific Time (1:30 P.M. Eastern Time).
Dec 22, 2022 09:46 am ET
Thinking about buying stock in Mullen Automotive, Cleveland-Cliffs, CarMax, IsoPlexis, or Teva Pharmaceutical?
NEW YORK, Dec. 22, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MULN, CLF, KMX, ISO, and TEVA.
Dec 22, 2022 04:00 am ET
Update on U.S. Regulatory Status of AVT02, Alvotech’s Proposed High-Concentration, Interchangeable Biosimilar to Humira®
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the FDA has granted a new Biosimilar User Fee Amendment (BsUFA) goal date of...
Nov 22, 2022 08:30 am ET
Teva Finalizes Nationwide Opioid Settlement Terms
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today that the company has finalized the documentation of its proposed nationwide opioid settlement with both the working group of States’ Attorneys General and the Multi-District Litigation Plaintiffs’ Executive Committee. Allergan has also finalized its settlement terms. As announced during the Company’s third quarter earnings call, Teva and Allergan have resolved their dispute with respect to Teva's indemnification obligations.
Nov 21, 2022 07:00 am ET
Teva Announces Appointment of Richard Francis as President and CEO
Teva Pharmaceutical Industries Ltd. (“Teva” or the “Company”) (NYSE and TASE: TEVA), today announced that the Company’s Board of Directors has appointed Richard Francis as President and Chief Executive Officer, effective January 1, 2023. In order to facilitate an orderly transition, Kåre Schultz and the Teva Board of Directors have mutually agreed that Mr. Schultz will retire from his current position as Chief Executive Officer, effective December 31, 2022.
Nov 14, 2022 08:01 am ET
Teva Announces Unique Collaboration with Rimidi to Expand the Reach of its Respiratory Digital Health Platform
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a new collaboration with Rimidi, a leading clinical management platform designed to optimize clinical workflows, enhance patient experiences and achieve quality objectives.
Nov 14, 2022 08:00 am ET
Teva Announces Unique Collaboration with HealthSnap to Expand the Reach of its Respiratory Digital Health Platform
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a new collaboration with HealthSnap, a leading full-service Virtual Care Management Platform for chronic disease management.
Nov 07, 2022 04:30 pm ET
Teva to Present Latest Research from the CONNECT1 and CONNECT2 Clinical Trials at the American College of Allergy, Asthma & Immunology (ACAAI) 2022 Annual Scientific Meeting
Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that new findings from the CONNECT clinical trial program assessing the use of the Digihaler System compared to standard of care (SoC) in asthma management will be presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2022 Annual Scientific meeting, being held November 10-14 in Louisville, Kentucky.
Nov 03, 2022 07:00 am ET
Teva Reports Third Quarter 2022 Financial Results
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended September 30, 2022.
Oct 25, 2022 10:00 am ET
Clinics Across Florida, New Jersey & California Advancing Mental Health in Underserved Communities – Awarded Funding from Teva Pharmaceuticals, Direct Relief and NAFC
Teva Pharmaceuticals, the National Association of Free and Charitable Clinics (NAFC) and Direct Relief announced today – as part of a two-year, $2 million commitment – the awarding of $825,000 in grant funding for 11 free and charitable clinics addressing mental health across Florida, New Jersey and California.
Oct 18, 2022 08:00 am ET
Teva Announces Results from 3-Year Study Assessing the Safety and Tolerability of AUSTEDO® (deutetrabenazine) Tablets for the Treatment of Chorea Associated with Huntington’s Disease
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced results from the ARC-HD (Alternatives for Reducing Chorea in Huntington’s Disease) trial, an approximately 3-year open-label, single-arm, 2-cohort, multicenter extension study evaluating the safety and tolerability of long-term treatment with AUSTEDO® (deutetrabenazine) tablets for chorea associated with Huntington’s Disease (HD). The ARC-HD study was conducted by Teva in partnership with the Huntington Study Group (HSG).
Oct 07, 2022 08:30 am ET
Teva Reaches Agreement With Arkansas to Settle the State’s Price Fixing Claims
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), has reached an agreement with the Attorney General of Arkansas to settle the state’s price-fixing claims against Teva. Under the terms of the settlement, Teva will pay the state $931,000, and the state will dismiss all of its claims against Teva and its affiliates once payment has been made.
Oct 06, 2022 04:00 pm ET
Teva to Host Conference Call to Discuss Third Quarter 2022 Financial Results at 8 a.m. ET on November 3, 2022
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2022 financial results on Thursday, November 3, 2022 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
Oct 06, 2022 08:34 am ET
Teva Announces Largest-Ever Trial to Collect Information from Patients and Physicians About TD, its Impact and Progression Over Time, and Evaluate Treatment-Related Outcomes
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the initiation of a 3-year longitudinal registry and study to assess the impact of tardive dyskinesia (TD) and real-world treatment patterns and outcomes. The Phase 4, multicenter, prospective, observational two-part study is the largest-ever study of its kind for TD and will collect information from both patients and physicians on TD. The study will evaluate how the condition progresses over time and impacts a person’s quality of life, as well as outcomes related to trea
Sep 30, 2022 08:00 am ET
Teva Reaches Agreement With Georgia to Settle the State’s Price Fixing Claims
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), has reached an agreement with the Attorney General (AG) of Georgia to settle the state’s price-fixing claims against Teva. Teva will pay the state $3.346 million as part of the settlement, and the state will dismiss all of its claims against Teva and its affiliates once payment has been made.
Sep 26, 2022 08:00 am ET
Teva Launches Honestly HD Website to Provide People Living With Huntington’s Disease (HD) Information, Inspiration and Resources on HD Chorea
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of the Honestly HD website, which aims to provide information, inspiration and resources to help people understand what to expect with Huntington’s Disease (HD) chorea – one of the most visible and treatable symptoms o
Sep 08, 2022 01:45 am ET
Studies Show Effectiveness of AJOVY®▼ (fremanezumab) for Treatment of Migraine in Patients With Co-morbid Depression
Teva Pharmaceutical Industries Ltd. today announces the results of two studies1,2 presented at the Migraine Trust International Symposium (MTIS) in London, UK, which demonstrate the efficacy of AJOVY▼ (fremanezumab) in migraine patients who also experience depression or anxiety. AJOVY▼ (fremanezumab) is indicated for the prevention of migraine in adults with at least 4 migraine days per month.8
Sep 07, 2022 08:00 am ET
CONNECT1 Study Published in Journal of Allergy and Clinical Immunology: In Practice Evaluates the Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder and Digihaler System to Help Imp
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that full results from the CONNECT1 study evaluating the ProAir® Digihaler® (albuterol sulfate) Inhalation Powder and the Digihaler System in the management of asthma patients compared to standard of care (SoC) albuterol reliever therapy, were published online ahead of print in The Journal of Allergy and Clinical Immunology: In Practice. The study found patients who used the ProAir Digihaler had reductions in weekly average daily
Aug 29, 2022 08:00 am ET
Teva to Present First Data Set from the CONNECT1 Clinical Trial on ProAir® Digihaler® (albuterol sulfate) Inhalation Powder at the European Respiratory Society (ERS) International Congress 2022
Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the first findings from the CONNECT clinical program on ProAir® Digihaler® (albuterol sulfate) inhalation powder with an integrated electronic module (eModule) will be presented at the European Respiratory Society (ERS) International Congress 2022, held September 4-6 in Barcelona, Spain.
Aug 29, 2022 02:00 am ET
European Commission grants marketing authorization for Ranivisio▼®* (ranibizumab), a biosimilar to Lucentis®**, for age-related macular degeneration (AMD) the most common cause of blindness in develop
Teva Pharmaceutical Industries Ltd. announces that the European Commission (EC) has granted a Marketing Authorization for Ranivisio (ranibizumab), a biosimilar of the ophthalmology treatment Lucentis across all five indications in adults for which Lucentis is authorized.
Aug 18, 2022 10:45 am ET
Thinking about buying stock in Endo International, FuelCell Energy, Cassava Sciences, Codiak BioSciences, or Teva Pharmaceutical?
NEW YORK, Aug. 18, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ENDP, FCEL, SAVA, CDAK, and TEVA.
Aug 17, 2022 12:38 pm ET
Thinking about buying stock in Genius Brands, Hill International, Tilray, Palisade Bio, or Teva Pharmaceutical?
NEW YORK, Aug. 17, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GNUS, HIL, TLRY, PALI, and TEVA.
Jul 27, 2022 08:30 am ET
Thinking about buying stock in Teva Pharmaceutical, Geovax Labs, VNET Group, Stronghold Digital Mining, or Enphase Energy?
NEW YORK, July 27, 2022  /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TEVA, GOVX, VNET, SDIG, and ENPH.
Jul 26, 2022 04:55 pm ET
Teva Reports Second Quarter 2022 Financial Results
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended June 30, 2022.
Jul 25, 2022 08:00 am ET
Certara Appoints Rosemary Crane as New Independent Board Member
Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of Rosemary Crane to its Board of Directors, effective July 21, 2022. Her appointment brings the company’s board of directors to eleven members. “We...
Jul 12, 2022 10:30 am ET
Teva Reaches Agreement With San Francisco to Settle Opioid-Related Claims
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and its affiliates, has reached an agreement with the City and County of San Francisco and the People of the State of California that settles opioid-related claims asserted on behalf of the County and City of San Francisco. The settlement will provide San Francisco $24.8 million over 13 years, as well as life-saving medicine generic Narcan® (naloxone hydrochloride nasal spray), valued at $20 million (wholesale acquisition cost), over 10 years.
Jul 01, 2022 08:34 am ET
Teva Announces Appointment of New Global R&D and Chief Medical Officer
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today the appointment of Eric A. Hughes, MD, PhD as Executive Vice President, Global R&D and Chief Medical Officer. Dr. Hughes will begin his employment on August 1, 2022, and will be based out of Teva's U.S. headquarters in Parsippany, NJ.
Jun 29, 2022 04:09 pm ET
Teva to Host Conference Call to Discuss Second Quarter 2022 Financial Results at 8 a.m. ET on July 27, 2022
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2022 financial results on Wednesday, July 27, 2022 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
Jun 24, 2022 12:54 pm ET
Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY® (fremanezumab)
Teva Pharmaceuticals Europe B.V. today announces promising interim results from its Pan-European Real World study (PEARL), presented for the first time at the European Academy of Neurology (EAN) Congress in Vienna, Austria.
Jun 09, 2022 05:15 pm ET
Teva Announces Settlement with Aurobindo Resolving AUSTEDO® (deutetrabenazine) Patent Dispute
Teva Branded Pharmaceutical Products R&D, Inc. and Auspex Pharmaceuticals, Inc., U.S. affiliates of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), have reached an agreement with Aurobindo to resolve the dispute over Aurobindo’s Abbreviated New Drug Application (“ANDA") for a generic deutetrabenazine product. Teva and Aurobindo have been involved in a patent infringement litigation in which Teva asserted a number of patents against Aurobindo that cover Teva’s AUSTEDO® (deutetrabenazine) product.
Jun 09, 2022 08:00 am ET
New Real-World Data Evaluating AJOVY® (fremanezumab-vfrm) Injection Use in Patients With Migraine Presented at 2022 American Headache Society Annual Meeting
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced results from a U.S. retrospective study examining real-world concomitant use of AJOVY (fremanezumab-vfrm) injection and gepants in the prevention and acute treatment of migraine. The data showing a reduction in monthly migraine days with the treatment combination were presented as a late-breaking poster during the 2022 American Headache Society (AHS) Annual Meeting held June 9-12, 2022, in Denver, Colorado.
Jun 09, 2022 07:45 am ET
Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2022 American Headache Society Annual Meeting
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that eight abstracts examining real-world data to better understand the use of AJOVY® (fremanezumab-vfrm) injection in patients with migraine will be presented at the 2022 American Headache Society (AHS) Annual Meeting held June 9-12, 2022, in Denver, Colorado.
Jun 08, 2022 09:00 am ET
Direct Relief, the National Association of Free and Charitable Clinics and Teva Pharmaceuticals Partner to Advance Access to Behavioral Health Services
Direct Relief, the National Association of Free and Charitable Clinics (NAFC), and Teva Pharmaceuticals today launched a new program to expand medication access and provide grant funding to free and charitable clinics that care for medically underserved patients suffering from depression and/or anxiety. Teva is providing free and charitable clinics with $2 million in grant funding over two years and making available, on a charitable basis, a portfolio of commonly used generic medications that treat depression and anxiety. The new pilot program – initially set in Florida, New Jersey and Califor
May 25, 2022 09:36 am ET
Teva Reaches Agreement With West Virginia to Settle the State’s Opioid-Related Claims
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and its affiliates, has reached an agreement with the Attorney General of West Virginia that settles the state’s and its subdivisions opioid-related claims. The settlement will provide West Virginia with $75 million over 15 years in addition to $8 million in attorneys’ fees and costs incurred during the trial. Teva will also provide its life-saving medicine, the generic version of Narcan® (naloxone hydrochloride nasal spray), valued at $27 million (wholesale acquisition cost), over 10
May 23, 2022 08:00 am ET
Teva Presents New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at 2022 American Psychiatric Association Annual Meeting
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new efficacy and safety data from a 3-year open-label extension (OLE) study on AUSTEDO® (deutetrabenazine) tablets in postmenopausal women with tardive dyskinesia (TD). These data will be presented at the 2022 American Psychiatric Association (APA) Annual Meeting, held May 21-25 in New Orleans and online June 7-10. In addition, new data assessing the psychological, social and physical impact of TD on patients and caregivers will also be featured in two posters
May 17, 2022 09:10 am ET
United Kingdom first to grant licence for Teva’s ophthalmology biosimilar Ongavia (ranibizumab)▼
Teva Pharmaceutical Industries Ltd welcomes the UK Medicines & Healthcare Regulatory Agency (MHRA) decision to grant a licence for Ongavia®, a biosimilar to Lucentis® (ranibizumab ), an eye injection. The United Kingdom is the first country in Europe to authorize commercialization of Ongavia® for the treatment of neovascular (wet) age-related macular degeneration (“AMD”). Ongavia® is also licenced for: the treatment of visual impairment due to diabetic macular oedema (DME); the treatment of proliferative diabetic retinopathy (PDR
May 17, 2022 08:00 am ET
Teva to Present Latest Research From Neurology Portfolio at the 2022 American Psychiatric Association Annual Meeting
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced four data presentations for AUSTEDO® (deutetrabenazine) tablets and TV-46000/mdc-IRM. These data will be presented at the American Psychiatric Association (APA) Annual Meeting held May 21-25, 2022 in New Orleans, Louisiana, and again virtually June 7-10, 2022.
May 17, 2022 07:45 am ET
Teva Announces New Findings Highlighting Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder to Address Asthma Treatment Challenges
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced new study findings based on newly established clinical thresholds on short-acting beta agonist (SABA) use that highlight real-world SABA usage among patients with asthma in the U.S. and the potential for ProAir® Digihaler® (albuterol sulfate) inhalation powder, a digital inhaler, to help inform treatment discussions and decisions. The findings were presented in a late-breaking oral session at the American Thoracic Society (ATS) 2022 Annual Meeting.
May 12, 2022 08:00 am ET
Teva to Present Findings on Short-Acting Beta Agonist (SABA) Use in Asthma Patients and the Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder to Help Inform Treatment Decisions at
Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new findings will be presented at the 2022 American Thoracic Society (ATS) 2022 Annual Meeting that apply clinical thresholds for short-acting beta agonist (SABA) use established by independent expert consensus to objective patient data from ProAir Digihaler (albuterol sulfate) Inhalation Powder. These findings are the first to examine daily SABA usage captured by the ProAir Digihaler based on the clinical thresholds and will be presented in a late-breaker oral
May 10, 2022 08:00 am ET
Teva Publishes 2021 ESG Progress Report, Showcasing Further Integration of ESG Into Business, Robust Targets and Strengthened ESG Governance Structure
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), a leading global pharmaceutical company providing medicines to nearly 200 million people daily, published its 2021 ESG Progress Report today. The report details how Teva further integrated ESG into its business strategy—implementing a
May 03, 2022 07:00 am ET
Teva Reports First Quarter 2022 Financial Results
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended March 31, 2022.
May 02, 2022 08:00 am ET
Teva Announces Settlement with Lupin Resolving AUSTEDO® (deutetrabenazine) Patent Dispute
Teva Branded Pharmaceutical Products R&D, Inc. and Auspex Pharmaceuticals, Inc., U.S. affiliates of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), have reached an agreement with Lupin to resolve the dispute over Lupin’s Abbreviated New Drug Application (“ANDA") for a generic deutetrabenazine product. Teva and Lupin have been involved in a patent infringement litigation in which Teva asserted a number of patents against Lupin that cover Teva’s AUSTEDO (deutetrabenazine) product.
Apr 19, 2022 05:15 pm ET
Teva and MedinCell Receive Complete Response Letter for TV-46000/mdc-IRM
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and MedinCell (Euronext: MEDCL) announced that the U.S. Food and Drug Administration (“FDA”) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) for the treatment of schizophrenia.
Apr 05, 2022 07:34 am ET
Teva Canada Charts a New Prescription for Care
- New initiatives planned to spark dialogue on future healthcare delivery –
Apr 04, 2022 04:05 pm ET
Teva to Host Conference Call to Discuss First Quarter 2022 Financial Results at 8 a.m. ET on May 3, 2022
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2022 financial results on Tuesday, May 3, 2022 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
Apr 01, 2022 08:00 am ET
Teva to Present New Analyses of AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine) Tablets at 2022 American Academy of Neurology Annual Meeting
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data for two of the company’s neurology portfolio treatments, AJOVY® (fremanezumab-vfrm) injection and AUSTEDO® (deutetrabenazine) tablets. These data will be presented at the American Academy of Neurology (AAN) Annual Meeting on April 2-7, 2022 in person and virtually on April 24-26, 2022.
Mar 30, 2022 09:09 am ET
Teva Reaches Agreement With Florida to Settle the State’s Opioid-Related Claims
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and its affiliates, has reached an agreement with the Attorney General of Florida that settles the state’s and its subdivisions opioid-related claims. The settlement will provide Florida $177 million over 15 years, as well as life-saving medicine generic Narcan® (naloxone hydrochloride nasal spray), valued at $84 million (wholesale acquisition cost), over 10 years.
Mar 21, 2022 02:55 pm ET
Teva Reaches Agreement With Rhode Island to Settle Opioid-Related Claims
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and its affiliates, has reached an agreement with the Attorney General of Rhode Island that settles the state’s and its subdivisions opioid-related claims. Under the terms of the settlement, Teva will pay Rhode Island $21 million over 13-years and will provide its recently launched, lifesaving medicine generic Narcan® (naloxone hydrochloride nasal spray) and a significant amount of buprenorphine naloxone (sublingual tablets) known by the brand name Suboxone®, valued at a combined $78.
Mar 07, 2022 08:00 am ET
Teva Announces Launch of a First Generic Version of Revlimid® (lenalidomide capsules), in the U.S.
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of a first generic version of Revlimid®1 (lenalidomide capsules), in 5mg, 10mg, 15mg, and 25mg strengths, in the United States.
Feb 09, 2022 09:50 am ET
Thinking about buying stock in Zosano Pharma, Banco Bradesco, AMC Entertainment, Snap, or Teva Pharmaceutical?
NEW YORK, Feb. 9, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZSAN, BBD, AMC, SNAP, and TEVA.
Feb 09, 2022 07:00 am ET
Teva Reports Fourth Quarter and Full Year 2021 Financial Results
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2021.
Feb 07, 2022 10:12 am ET
Teva Reaches Agreement With Texas to Settle the State’s Opioid-Related Claims
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and its affiliates, has reached an agreement with the Attorney General (AG) of Texas that settles the state’s and its subdivisions opioid-related claims. Under the terms of the settlement, Teva will pay Texas $150 million over a 15-year time period and will provide the recently launched, lifesaving medicine generic Narcan® (naloxone hydrochloride nasal spray), valued at $75 million (wholesale acquisition cost) over 10 years.
Feb 01, 2022 08:00 am ET
Research Finds COVID Pandemic Worsened Health Equity Gap
As we approach the end of year two of the COVID-19 pandemic, 70% of healthcare consumers see a doctor or access health services regularly, while 25% of all healthcare consumers in the U.S. say it is difficult for them to access healthcare from high-quality doctors or hospitals. These findings were captured in a new national survey, State of Access to Healthcare in America, released today by Teva Pharmaceuticals (NYSE and TASE: TEVA) in collaboration with the Morehouse School of Medicine. The survey uncovered that access barriers due to the COVID-19 pandemic impacted groups that are already lik
Jan 18, 2022 08:00 am ET
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Results and 2022 Financial Guidance at 8 a.m. ET on February 9, 2022
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2021 financial results, as well as on its financial guidance for 2022, on Wednesday, February 9, 2022 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
Jan 04, 2022 01:35 pm ET
Teva to Present at the 40th Annual J.P. Morgan Healthcare Conference
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that President & CEO Kåre Schultz will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022. The presentation will begin at 9:45 A.M. Eastern Time.
Dec 31, 2021 09:45 am ET
Thinking about buying stock in SuperCom, Teva Pharmaceutical, Future Fintech Group, Spruce Biosciences, or CooTek?
NEW YORK, Dec. 31, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SPCB, TEVA, FTFT, SPRB, and CTK.
Dec 30, 2021 01:29 pm ET
Teva Statement Following New York Jury Ruling in Opioids Trial
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, Ltd. (NYSE and TASE: TEVA) strongly disagrees with today’s outcome and will prepare for a swift appeal as well as continue to pursue a mistrial.
Dec 22, 2021 04:30 pm ET
Teva Announces Launch of First-to-Market Generic Version of Narcan® (Naloxone Hydrochloride Nasal Spray), in the U.S.
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of a first-to-market generic version of Narcan®1 (naloxone hydrochloride nasal spray), in the United States.
Dec 01, 2021 08:00 am ET
Teva Announces Launch of an Authorized Generic of Epiduo® Forte Gel (adapalene and benzoyl peroxide gel 0.3%/2.5%), in the U.S.
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of an authorized generic of Epiduo®1 Forte Gel (adapalene and benzoyl peroxide gel 0.3%/2.5%), in the United States.
Nov 25, 2021 12:00 pm ET
Quantum Genomics signs an exclusive license agreement with Teva Israel Ltd.
Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new drug class directly targeting the brain to treat difficult-to-treat/resistant hypertension, has today announced the...
Nov 10, 2021 09:17 am ET
Teva Announces Early Tender Results of its Debt Tender Offer, Increase of the Maximum Tender Amount and Election of Early Settlement
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the early tender results in connection with its previously announced tender offers (the “Offers”) and that it is increasing the combined aggregate purchase price (exclusive of accrued and unpaid interest) (the “Total Maximum Amount”) from $3,500,000,000 to $4,000,000,000 for the following series of notes issued by finance subsidiaries of Teva and guaranteed by Teva:
Nov 03, 2021 06:00 am ET
Teva Becomes First Pharmaceutical Company to Execute Sustainability-linked Bond Tied to both Climate and Access to Medicine Targets
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced ambitious commitments to address two of today’s greatest global crises—access to medicines and climate change—tied to its recently issued $5 billion sustainability-linked bond. The bond is linked to three targets, including a 25% reduction in Scope 1 and 2 greenhouse gas (GHG) emissions and a 150% increase in access to essential medicines for patients in low- and middle-income countries (LMICs) by the end of 2025.
Nov 02, 2021 05:31 pm ET
Teva Announces Successful Upsize of Sustainability-Linked Senior Notes Offering and Pricing of $5,000,000,000 of Sustainability-Linked Senior Notes
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it successfully upsized and priced approximately $5,000,000,000 (equivalent) of its debut sustainability-linked senior notes (the “Notes”). The principal amount of the offering was increased from the previously announced offering size of $4,000,000,000 (equivalent). Teva expects to use the net proceeds from the offerings to (i) fund the announced tender offer to purchase, for cash, its 1.250% Senior Notes due 2023, its 2.800% Senior Notes due 2023, its 3.250% Senior Notes due 2022, its 2.950%
Nov 02, 2021 08:35 am ET
Thinking about buying stock in Sab Biotherapeutics, Artelo Biosciences, Under Armour, Endo International, or Teva Pharmaceutical?
NEW YORK, Nov. 2, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SABS, ARTL, UAA, ENDP, and TEVA.
Nov 01, 2021 10:00 pm ET
California Judge Rules That Teva Did Not Cause a Public Nuisance or Make False or Misleading Statements About Opioids
Today, Orange County, California, Superior Court Judge Peter Wilson issued a decision finding that Teva did not cause a public nuisance in Orange County, Los Angeles County, Santa Clara County and the City of Oakland and that Teva did not make any false or misleading statements in connection with marketing prescription opioids in California.
Oct 30, 2021 04:00 pm ET
New Phase 3 Data Presented at Psych Congress 2021 Showed TV-46000/mdc-IRM Significantly Prolonged Time to Impending Relapse Compared to Placebo in Patients with Schizophrenia
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced results from the pivotal Phase 3 Risperidone Subcutaneous Extended-release (RISE) study comparing TV-46000/mdc-IRM once monthly (q1m) and TV-46000/mdc-IRM once every two months (q2m) with placebo (1:1:1) in patients with schizophrenia who underwent stabilization on oral risperidone. Results showed treatment with TV-46000 (overall, q1m or q2m) significantly prolonged time to relapse, decreased proportions of patients with impending relapse at week 24 and demo
Oct 27, 2021 07:15 am ET
Teva Announces $3,500,000,000 Debt Tender Offers for Notes Due 2022-2024
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it has commenced tender offers (the “Offers”) to purchase for cash for a combined aggregate purchase price (exclusive of accrued and unpaid interest) of up to $3,500,000,000 (the “Total Maximum Amount”) of the following series of notes issued by finance subsidiaries of Teva and guaranteed by Teva:
Oct 27, 2021 07:15 am ET
Teva Announces Launch of $4,000,000,000 Offering of Sustainability-linked Senior Notes
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today its intention to issue $4,000,000,000 of sustainability-linked senior notes. The notes offering reflects Teva’s strong environmental, social and governance (ESG) commitment to some of the greatest challenges of our time by setting novel ambitious targets to increase access to medicines in low and middle-income countries by 150%, and new ambitious climate action targets, including a 25% reduction of Scope 1 and 2 greenhouse emissions by 2025 in alignment with the Paris Climate Agreement.
Oct 27, 2021 07:00 am ET
Teva Reports Third Quarter 2021 Financial Results
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended September 30, 2021.
Oct 26, 2021 04:45 pm ET
Teva and MODAG Announce Licensing Collaboration for Neurodegenerative Disease Drug Candidate
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and MODAG GmbH today announced a strategic collaboration on the exclusive worldwide licensing and development of MODAG's lead compound anle138b and a related compound, sery433.
Oct 21, 2021 08:00 am ET
Teva to Present New Data from Growing Mental Health Portfolio at Psych Congress 2021
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced 25 presentations examining new Phase 3 clinical data, post hoc analyses and open-label extension (OLE) studies for both TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) and AUSTEDO® (deutetrabenazine) tablets. Study findings will be presented at the upcoming 2021 Psych Congress Annual Meeting taking place Oct. 29-Nov. 1, 2021 in San Antonio, TX (in addition to virtual participation).
Oct 13, 2021 02:00 am ET
New Safety Data on treatment with COPAXONE® (glatiramer acetate) of Breastfeeding Mothers who Live with Relapsing Multiple Sclerosis
The new analysis of COBRA study, which currently represents the largest dataset of child outcomes breastfed by mothers treated with GA, assessed 99 mothers with MS and their infants. It concluded that no evidence was found to suggest that infants were adversely affected by maternal exposure to GA during pregnancy and breastfeeding with regard to hospitalisations and antibiotic treatments, developmental delay, or growth in the first 18 months of life1.
Oct 01, 2021 10:20 am ET
Teva to Host Conference Call to Discuss Third Quarter 2021 Financial Results at 8 a.m. ET on October 27, 2021
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its financial results for the third quarter of 2021 on Wednesday, October 27, 2021 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
Sep 30, 2021 08:00 am ET
Teva to Present 8 Abstracts on AJOVY® (fremanezumab-vfrm) Injection and Hold Symposium on Healthcare Disparities at WCN
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that 8 presentations examining Phase 2b/3 data, pooled analyses and open-label extension (OLE) study data for AJOVY (fremanezumab-vfrm) injection will be presented at the 25th World Congress of Neurology (WCN), taking place virtually on Oct. 3-7, 2021.
Sep 30, 2021 07:30 am ET
Teva Enlists Sarah Michelle Gellar to Launch “Inhaler Tales” Campaign to Raise Awareness About Inhaler Use in Asthma and COPD
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of Inhaler Tales – a national campaign aimed at raising awareness about the role inhaler misuse may play in inadequate disease control.1
Sep 28, 2021 12:40 pm ET
Teva Reaches Agreement with Louisiana to Settle the State’s Opioid-Related Claims
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), has reached an agreement with the Attorney General (AG) of Louisiana that settles the state’s opioid-related claims. The agreement is contingent on confirmation from the state by November 2, 2021 that all political subdivisions will release Teva as part of the settlement.
Sep 08, 2021 08:00 am ET
Late-Breaking Data at the International Headache Society & European Headache Federation Joint Congress 2021 Showed AJOVY® (fremanezumab-vfrm) Injection Reduced More Monthly Migraine Days in a Network
Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced results from a network meta-analysis examining the efficacy of AJOVY (fremanezumab-vfrm), atogepant and Nurtec® ODT (rimegepant) in the preventive treatment of episodic migraine (EM). This data will be presented as a late-breaker ePoster during the International Headache Society (IHS) and European Headache Federation (EHF) Joint Congress taking place virtually on Sept. 8-12, 2021.
Aug 31, 2021 04:15 pm ET
Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with Schizophrenia
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and MedinCell (Euronext: MEDCL) announced today that the New Drug Application (NDA) for TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) for the treatment of schizophrenia has been accepted by the U.S. Food and Drug Administration (FDA).
Aug 30, 2021 08:00 am ET
Showcasing Teva’s Commitment to Helping Patients Have More Migraine-Free Days, 18 Abstracts will be presented, Including One Late-Breaker, on AJOVY® (fremanezumab-vfrm) Injection at the International
Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that 17 presentations, including one late-breaker, examining post hoc, real-world and survey data for AJOVY (fremanezumab-vfrm) injection will be presented at the International Headache Society and European Headache Federation Joint Congress, taking place virtually on Sept. 8-12, 2021.
Aug 20, 2021 08:00 am ET
Teva Announces Post Hoc Analysis of Long-Term Data Examining Treatment with AUSTEDO® (deutetrabenazine) Tablets in Adult Patients with Tardive Dyskinesia
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced results from a post hoc analysis of a long-term, 3-year open-label extension (OLE) study examining efficacy and safety endpoints for the use of AUSTEDO (deutetrabenazine) tablets in younger (
Jul 28, 2021 10:45 am ET
Thinking about buying stock in Teva Pharmaceutical, Tencent Music Entertainment, Xpeng, Vipshop Holdings, or Asensus Surgical?
NEW YORK, July 28, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TEVA, TME, XPEV, VIPS, and ASXC.
Jul 28, 2021 07:30 am ET
Teva Generic Medicines Saved the United States $28.8 Billion in 2020, and a Total of $43.1 Billion Across Major Markets, According to Independent Analysis
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) released a new report highlighting the billions of dollars saved by the healthcare system due to its generic medicines, and the Company’s contribution to economies in 2020.
Jul 28, 2021 07:00 am ET
Teva Reports Second Quarter 2021 Financial Results
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended June 30, 2021.
Jul 21, 2021 08:00 am ET
Teva Announces Changes to Executive Management Team
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced changes to its leadership team. Brendan O’Grady, Executive Vice President, North America Commercial, will leave Teva to pursue a career opportunity outside of the pharmaceutical industry, and Sven Dethlefs, who currently serves as Teva’s Executive Vice President, Global Marketing and Portfolio and International Markets Commercial has been appointed the new head of North America Commercial.
Jul 20, 2021 10:50 am ET
Thinking about buying stock in Ardelyx, AstraZeneca, Rocket Companies, Teva Pharmaceutical, or JetBlue Airways?
NEW YORK, July 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ARDX, AZN, RKT, TEVA, and JBLU.
Jul 01, 2021 12:14 pm ET
Teva to Host Conference Call to Discuss Second Quarter 2021 Financial Results at 8 a.m. ET on July 28, 2021
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its financial results for the second quarter of 2021 on Wednesday, July 28, 2021 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
Jun 28, 2021 08:00 am ET
Teva and Bioeq Announce Commercial Partnership for Biosimilar
Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) and Bioeq AG ("Bioeq") today announced that they have entered into a strategic partnership for the exclusive commercialization of Bioeq's FYB201, a biosimilar candidate to Lucentis® (ranibizumab) in Europe, Canada, Israel and New Zealand.
Jun 23, 2021 08:12 am ET
Teva Announces Ministry of Health, Labour and Welfare Approves AJOVY® (fremanezumab) Injection in Japan for the Preventive Treatment of Migraine in Adults
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the Ministry of Health, Labour and Welfare (MHLW) has approved the use of AJOVY (fremanezumab) injection for the preventive treatment of migraine in adults in Japan.
Jun 22, 2021 05:18 pm ET
Teva Announces Its Launch of the First Generic PERFOROMIST®, Formoterol Fumarate Inhalation Solution, 20 mcg/2 ML, Used to Treat Chronic Obstructive Pulmonary Disease (COPD), in the United States
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced its U.S. launch of the first generic version of twice daily PERFOROMIST®, formoterol fumarate inhalation solution, 20 mcg/2 ML, indicated to treat bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Jun 16, 2021 07:36 am ET
Teva Announces the U.S. Launch of its Generic Version of SOOLANTRA® (ivermectin) Cream, 1% for Once Daily Treatment of Rosacea
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.(NYSE and TASE: TEVA), today announced the U.S. launch of its generic version of once daily SOOLANTRA® (ivermectin) Cream, 1% for the treatment of inflammatory lesions of rosacea.
Jun 03, 2021 08:15 am ET
New Clinical and Real-World Data Evaluating Efficacy of AJOVY® (fremanezumab-vfrm) Injection Presented at 2021 American Headache Society (AHS) Annual Meeting
Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from clinical and real-world analyses examining the efficacy of AJOVY® (fremanezumab-vfrm) for the treatment of migraine, which is being presented at the American Headache Society (AHS) annual meeting, taking place virtually on June 3-6.
Jun 03, 2021 08:00 am ET
Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2021 American Headache Society (AHS) Annual Meeting, Showcasing Teva’s Longstanding Heritage in the Management of Migraine
Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that 11 presentations examining clinical and real-world data for AJOVY® (fremanezumab-vfrm) injection will be presented at the 2021 American Headache Society (AHS) Annual Meeting, taking place virtually June 3-6.
May 17, 2021 01:03 pm ET
Teva Announces the U.S. Launch of the First Generic Version of THIOLA® (tiopronin) tablets
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced its launch of the first available generic version, in the U.S., of THIOLA® (tiopronin) tablets, indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine (kidney) stone formation in adults and pediatric patients 9 years of age and older with severe homozygous cystinuria, who are not responsive to these measures alone.
May 10, 2021 08:00 am ET
Teva to Highlight Research in Respiratory Care at Upcoming 2021 American Thoracic Society International Conference
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that it will present two new e-posters at the upcoming American Thoracic Society (ATS) International Conference, taking place virtually May 14-19, 2021. One of the two e-posters details data on increased short-acting beta-agonist (SABA) use in patients with poorly controlled asthma, as measured by Teva’s ProAir® Digihaler® (albuterol sulfate) inhalation powder, a SABA inhaler prescribed to people 4 years of age and older to treat or prevent bronchosp
May 05, 2021 08:00 am ET
Teva Announces New Environmental, Social and Governance (ESG) Strategy and Goals in 2020 Report
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2020 Environmental, Social and Governance (ESG) Progress Report detailing the company’s efforts to advance health and equity, minimize its impa
May 04, 2021 11:14 am ET
Teva Announces Launch of its Generic Erythromycin Tablets USP, Used to Treat or Prevent a Variety of Bacterial Infections, in the United States
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of its 250 mg and 500 mg strength generic Erythromycin tablets—a therapeutic equivalent for the reference listed drug (RLD) Erythromycin Tablets from Arbor Pharmaceuticals. Teva generic Erythromycin tablets are indicated to treat a variety of bacterial infections, and to prevent initial or recurrent attacks of rheumatic fever in patients allergic to penicillin.
May 03, 2021 08:00 am ET
Teva to Present New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at American Psychiatric Association Annual Meeting
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from the 3-year open-label extension study of AUSTEDO® (deutetrabenazine) Tablets that studied patients with tardive dyskinesia (TD) will be presented at the 2021 American Psychiatric Association (APA) Virtual Annual Meeting, being held online from May 1-3.
Apr 29, 2021 04:18 pm ET
Teva Announces the Launch of the First Generic Version of Absorica® (isotretinoin) Capsules, for the Treatment of Severe Recalcitrant Nodular Acne in Patients 12 Years of Age and Older, in the United
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced its launch of the first available 10 mg, 20 mg, 25 mg, 30 mg, 35 mg and 40 mg strength generic version of Absorica®1 (isotretinoin) capsules for the treatment of severe recalcitrant nodular acne in non-pregnant patients 12 years of age and older with multiple inflammatory nodules with a diameter of 5 mm or greater.
Apr 28, 2021 07:00 am ET
Teva Reports First Quarter 2021 Financial Results
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended March 31, 2021.
Apr 27, 2021 08:00 am ET
Teva to Present New Analyses of AUSTEDO® (deutetrabenazine) Tablets and Assessment of Schizophrenia Clinical Outcomes at Upcoming 2021 American Psychiatric Association Annual Meeting
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced four new posters examining long-term analyses of AUSTEDO® (deutetrabenazine) tablets and clinical outcome measures in schizophrenia will be presented at the upcoming 2021 American Psychiatric Association (APA) Annual Meeting taking place May 1-3, 2021.
Apr 23, 2021 11:09 am ET
Teva Announces Launch of its Generic Version of Canasa® (mesalamine) Suppositories To Treat Adults with Active Ulcerative Proctitis (ulcerative rectal colitis), in the United States
Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of its 1000 mg strength generic version of Casana®1 (mesalamine) suppository medicine used to treat adults with active ulcerative proctitis (ulcerative rectal colitis), in the U.S.
Apr 19, 2021 08:00 am ET
New Clinical and Real-World Data Evaluating Efficacy of AJOVY® (fremanezumab-vfrm) Injection and Reduction of Migraine Burden Presented at 2021 American Academy of Neurology Virtual Annual Meeting
Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from clinical and real-world analyses examining the efficacy of AJOVY® (fremanezumab-vfrm). These data are being presented at the 2021 American Academy of Neurology (AAN) Virtual Annual Meeting, taking place April 17-22.
Apr 15, 2021 08:00 am ET
Teva to Present New Analyses of AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine) Tablets at Upcoming 2021 American Academy of Neurology Virtual Annual Meeting, Highlighting Teva’s
Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced 19 presentations examining clinical and real-world data for AJOVY® (fremanezumab-vfrm) injection and AUSTEDO® (deutetrabenazine) tablets will be presented at the upcoming 2021 American Academy of Neurology (AAN) Virtual Annual Meeting, taking place April 17-22.
Apr 08, 2021 07:30 am ET
Teva Canada Announces New Autoinjector for AJOVY® for the Preventive Treatment of Migraine in Adults
Teva Canada, a subsidiary of Teva Pharmaceutical Industries Ltd., today announced the launch and availability of a new autoinjector for AJOVY® (fremanezumab). AJOVY® is a subcutaneous injection for the preventive treatment of migraine in adults who have at least four migraine days per month. When launched in 2020, AJOVY® was available in a prefilled syringe only. The product is now available in two latex-free1 formats: a new autoinjector and a prefilled syringe.
Apr 06, 2021 09:42 am ET
Teva to Host Conference Call to Discuss First Quarter 2021 Financial Results at 8 a.m. ET on April 28, 2021
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its financial results for the first quarter on Wednesday, April 28, 2021 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
Apr 06, 2021 07:30 am ET
Teva Canada Amplifies Commitment to Canadian Caregivers
Extending its ongoing commitment to caregivers through the Caregiver-Friendly Pharmacy (CFP) program, and recognizing the significant toll COVID-19 has had on the caregiver community over the past year, Teva Canada today unveiled new resources and programming to supp
Mar 08, 2021 02:46 pm ET
Teva Announces Launch of First Generic Version of AZOPT® (brinzolamide ophthalmic suspension) 1%, used to treat high pressure inside the eye, in the United States
Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd.(NYSE and TASE: TEVA), today announced its launch of the first available generic version of AZOPT® (brinzolamide ophthalmic suspension) 1%, approved by the US Food and Drug Administration to treat high pressure inside the eye due to ocular hypertension and open-angle glaucoma. Brinzolamide ophthalmic suspension 1% works by decreasing the amount of fluid within the eye.
Mar 01, 2021 04:00 pm ET
Teva to Present at the J.P. Morgan 2021 Global High Yield and Leveraged Finance Conference
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Executive Vice President & CFO Eli Kalif will present at the J.P. Morgan 2021 Global High Yield and Leveraged Finance Conference on Tuesday, March 2, 2021 at 8:30 a.m. Eastern Time.
Feb 26, 2021 08:00 am ET
New Study Published in Cephalalgia Identifies Mechanistic Differences Among CGRP Migraine Treatments
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) highlights results from the in vitro study “Migraine Therapeutics Differentially Modulate the CGRP Pathway,” which were published online by Cephalalgia, a
Feb 10, 2021 07:00 am ET
Teva Reports Fourth Quarter and Full Year 2020 Financial Results
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2020.
Jan 14, 2021 05:17 pm ET
Teva Announces Launch of a Generic Version of NuvaRing® (etonogestrel and ethinyl estradiol) Vaginal Ring in the United States
Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd.(NYSE and TASE: TEVA), today announced the availability of a generic version of NuvaRing®1 (etonogestrel and ethinyl estradiol vaginal ring), 0.120 mg/0.015 mg per day, in the U.S. Teva’s AB-rated and bioequivalent etonogestrel and ethinyl estradiol vaginal ring, is an estrogen/progestin combination hormonal contraceptive (CHC) indicated for use by women to prevent pregnancy.
Jan 08, 2021 03:01 pm ET
Teva to Host Conference Call to Discuss Fourth Quarter 2020 Financial Results and 2021 Financial Guidance at 8 a.m. ET on February 10, 2021
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2020 financial results, as well as on its financial guidance for 2021, on Wednesday, February 10, 2021 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
Jan 07, 2021 04:00 pm ET
Teva to Present at the 39th Annual J.P. Morgan Healthcare Conference
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that President & CEO Kåre Schultz will present at the 39th Annual J.P. Morgan Healthcare Conference in San Francisco, California on Wednesday, January 13, 2021. The presentation will begin at 8:20 A.M. Eastern Time.
Jan 07, 2021 08:00 am ET
Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia
Teva Pharmaceuticals Industries Ltd. (NYSE and TASE: TEVA) and MedinCell (Euronext: MEDCL) today announced positive results for study TV46000-CNS-30072 (the RISE study – The Risperidone Subcutaneous Extended-Release Study), a Phase 3 clinical trial designed to evaluate the efficacy of TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) as a treatment for patients with schizophrenia. Trial enrollment was open to patients 13-65 years of age. In the RISE study, patients treated with the investigational subcutaneous risperidone injection either monthly (q1M)
Nov 23, 2020 08:52 am ET
DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Teva Pharmaceuticals Industries Limited and Encourages Investors with Losses of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Teva Pharmaceuticals Industries Limited (“Teva” or “the Company”) (NYSE:
Nov 14, 2020 02:20 pm ET
ROSEN, A LEADING AND RESPECTED LAW FIRM, Reminds Teva Pharmaceuticals Industries Limited Investors of the Important November 23 Deadline in Securities Class Action; Encourages Investors with Losses in
NEW YORK, Nov. 14, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds the purchasers of the securities of Teva Pharmaceuticals Industries Limited (NYSE: TEVA) between October 29, 2015 and August 18, 2020, inclusive (the "Class Period"), of the important November 23, 2020 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for Teva investors under the federal securities laws.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.